Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2013, 22(5):388-394

Combination of ACE inhibitor perindopril-arginine and calcium channel blocker amlodipine: more than only a reduction of increased blood pressure

Remková A
Centra hemostázy a trombózy, HemoMedika Bratislava, s. r. o., Slovenská republika

The present management of hypertension focuses not only on blood pressure (BP) values, but also on additional cardiovascular (CV) risk factors. Considering total CV risk in addition to BP levels is aimed to maximize effectiveness of the therapy since in high-risk individuals antihypertensive treatment strategies may be different from those to be implemented in lower-risk individuals. The 2013 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines on hypertension management now advocate combining two antihypertensive agents for the initial treatment of patients at high CV risk. Also they acknowledge the benefits of simplicity and better compliance with antihypertensive fixed-dose combinations. Those combinations that have been successfully used in trials should be preferable. One two-drug combination recommended by the ESH/ESC is an angiotensin converting enzyme (ACE) inhibitor/calcium channel blocker (CCB), such as perindopril/amlodipine. The efficacy and safety of perindopril-arginine/amlodipine combination is well established. The best evidence comes from outcome studies with perindopril/ amlodipine combination, particularly the ASCOT trial. Moreover, the perindopril/amlodipine combination therapy can reduce the risk of developing resistant hypertension. In a real-life practice setting, further effective, safe and sustained 24-h ambulatory BP reductions were obtained with the perindopril/amlodipine fixed-dose combination in hypertensive patients uncontrolled on ACE inhibitor and/or CCB.

Keywords: combination therapy; arterial hypertension; perindopril-arginine, amlodipine; fixed-dosed combinations

Published: May 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Remková A. Combination of ACE inhibitor perindopril-arginine and calcium channel blocker amlodipine: more than only a reduction of increased blood pressure. Cardiology Letters. 2013;22(5):388-394.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; doi:10.1093/eurheartj/eht151. Go to original source...
    2. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM. Estimation of tenyear risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003. Go to original source...
    3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte O, Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012;33:1635-1701. Go to original source...
    4. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300. Go to original source...
    5. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupta J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investi­gators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428. Go to original source...
    6. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Neminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. Go to original source...
    7. Dolan E, Stanton AV, Thom S et al. on behalf of the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 2009;27:876-885. Go to original source...
    8. Poulter NR, Wedel H, Dahlöf B. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913. Go to original source...
    9. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM, on behalf of the EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010;159:795-802. Go to original source...
    10. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788. Go to original source...
    11. Remková A, Remko M. El Sistema Renina-Angiotensina-Aldoste­ rona (SRAA) y el Estado Protrombótico en la Hipertensión Arterial. Salud(i)Ciencia 2011;18(3):220-224.
    12. Pella D, Remko M. Fixná kombinácia perindopril arginín/indapamid - existuje lepšia ochrana hypertonikov pred cievnymu mozgovými príhodami? Interná med 2012;12(6):262-266.
    13. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlőf B, Poulter NR, on behalf of the ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at highrisk. J Hypertens 2011;29(10):2004-2013. Go to original source...
    14. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225. Go to original source...
    15. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905. Go to original source...
    16. Nagy VL. Twenty-Four-Hour Ambulatory Blood Pressure Reduction with a Perindopril/Amlodipine Fixed-Dose Combination. Clin Drug Investig 2013;33(5): DOI 10.1007/s40261-013-0086-9. Go to original source...
    17. Remko M. Acidity, Lipophilicity, Solubility, Absorption, and Polar Surface Area of Some ACE Inhibitors. Chem Papers 2007;61:133-141. Go to original source...
    18. Remko M, Bojarska J, Ježko P, Sieroń L, Olczak A, Maniukiewicz W. Crystal and molecular structure of perindopril erbumine salt. J Mol Struct 2011;997:103-109. Go to original source...
    19. Remko M. Molecular structure and stability of perindopril erbu­ mine and perindopril L-arginine complexes. Eur J Med Chem 2009;44:101-108. Go to original source...
    20. Remko M, Bojarska J, Ježko P, Maniukiewicz W, Olczak A. Molecular structure of antihypertensive drug perindopril, its active metabolite perindoprilat and impurity F. J Mol Struct 2013;1036: 292-297. Go to original source...

    Return to the content